Ann: Imagion Biosystems December 2021 Investor Newsletter, page-46

I will not say it’s undervalued until its safety and efficiency been approved, many things should be considered when we talk about the sp, and management is one of the most crucial one, even more important than its product sometimes. Bad management can’t communicate with the market efficiently, this is why some companies have to exit even they have “breakthrough” technology. I agree that they don’t need to put up a price sensitive announcement every one or two months, but keep repeating the same information and let the market to guess is not a good idea, many may think they are hiding something or lack of progress.